GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
News|Articles|February 29, 2024
Recap: Eating Disorders 2024
Author(s)Erin O'Brien
Here’s a look back at selections from our February content series on eating disorders.
Advertisement
Advertisement
Related to this article
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
Male athletes with anorexia often go unnoticed as “discipline”; learn red flags, sport-specific risks, health consequences, and treatment steps for earlier diagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
2
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
3
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
4
The Lingering 'Blah': Residual Symptoms and Sleep as an Early Warning Sign
5